www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Amgen_Announces_Webcast_of_2008_Second_Quarter_Financial_Results_755084Amgen (NASDAQ:AMGN) today announced that it plans to report its second quarter financial results on Monday, July 28, 2008 after the close of the financial markets. The announcement will be followed by a conference call with the investment ...http://www.finanzen.net/nachricht/Amgen_Announces_Webcast_of_2008_Second_Quarter_Financial_Results_755084http://www.finanzen.net/nachricht/Please_kill_this_story__752951Business Wire requests that BW5644, Amgen Inc. press release entited "FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP" be killed. The release was issued prematurely by Business Wire. ...http://www.finanzen.net/nachricht/Please_kill_this_story__752951http://www.finanzen.net/nachricht/Amgen_Announces_Positive_Top_Line_Results_for_Denosumab_Treatment_of_Bone_Loss_in_Men_With_Non_Metastatic_Prostate_Cancer_Undergoing_Androgen_Deprivation_Therapy_752935Amgen (NASDAQ:AMGN) today announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate ...http://www.finanzen.net/nachricht/Amgen_Announces_Positive_Top_Line_Results_for_Denosumab_Treatment_of_Bone_Loss_in_Men_With_Non_Metastatic_Prostate_Cancer_Undergoing_Androgen_Deprivation_Therapy_752935http://www.finanzen.net/nachricht/FDA_Approves_Nplate_TM_for_Long_Term_Treatment_of_Adult_Chronic_ITP_752911Amgen Inc. (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nplate™ (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) ...http://www.finanzen.net/nachricht/FDA_Approves_Nplate_TM_for_Long_Term_Treatment_of_Adult_Chronic_ITP_752911http://www.finanzen.net/nachricht/Amgen_and_Ortho_Biotech_Settle_Antitrust_Suit_752509Amgen (NASDAQ:AMGN) today announced that it has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products L.P. (Ortho Biotech). Ortho Biotech, a subsidiary of Johnson & Johnson (NYSE: JNJ), had ...http://www.finanzen.net/nachricht/Amgen_and_Ortho_Biotech_Settle_Antitrust_Suit_752509http://www.finanzen.net/nachricht/Amgen_Commits_to_PhRMA_s_Enhanced_Code_on_Interactions_with_Healthcare_Professionals_as_Part_of_the_Company_s_Clearly_Amgen_Initiative_751649Amgen (NASDAQ: AMGN) today announced its intent to comply with the Pharmaceutical Research and Manufacturers of America’s (PhRMA) revised "Code on Interactions with U.S. Healthcare Professionals.” The company’s announcement ...http://www.finanzen.net/nachricht/Amgen_Commits_to_PhRMA_s_Enhanced_Code_on_Interactions_with_Healthcare_Professionals_as_Part_of_the_Company_s_Clearly_Amgen_Initiative_751649http://www.finanzen.net/nachricht/New_Data_Show_Preemptive_Treatment_May_Significantly_Reduce_Skin_Toxicities_in_Patients_Receiving_Vectibix_R__Panitumumab__746671Amgen (NASDAQ: AMGN) today announced updated results from the "STEPP" (Skin Toxicity Evaluation Protocol with Panitumumab) trial, the first prospective study to examine differences between preemptive and reactive skin treatment for ...http://www.finanzen.net/nachricht/New_Data_Show_Preemptive_Treatment_May_Significantly_Reduce_Skin_Toxicities_in_Patients_Receiving_Vectibix_R__Panitumumab__746671http://www.finanzen.net/nachricht/Enbrel_R__etanercept_Application_for_the_Treatment_of_Pediatric_Psoriasis_to_be_Discussed_at_FDA_Dermatologic_and_Ophthalmic_Drugs_Advisory_Committee_DODAC_Meeting_742793Amgen (NASDAQ:AMGN) announced that the supplemental Biologics License Application (sBLA) for ENBREL for the treatment of pediatric patients with chronic moderate to severe plaque psoriasis who have tried another therapy will be discussed ...http://www.finanzen.net/nachricht/Enbrel_R__etanercept_Application_for_the_Treatment_of_Pediatric_Psoriasis_to_be_Discussed_at_FDA_Dermatologic_and_Ophthalmic_Drugs_Advisory_Committee_DODAC_Meeting_742793http://www.finanzen.net/nachricht/Romiplostim_Data_Show_Potential_Long_Term_Efficacy_and_Safety_in_Adults_with_Chronic_ITP_741102Amgen Inc. (NASDAQ: AMGN) today announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic ...http://www.finanzen.net/nachricht/Romiplostim_Data_Show_Potential_Long_Term_Efficacy_and_Safety_in_Adults_with_Chronic_ITP_741102http://www.finanzen.net/nachricht/Amgen_SVP_of_North_American_Commercial_Operations_James_Daly_to_Present_at_the_Goldman_Sachs_Healthcare_Conference_738720Amgen (NASDAQ:AMGN) Senior Vice President of North American Commercial Operations James Daly will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11, 2008 beginning at 8:40 a.m. Pacific Time. Live audio of the ...http://www.finanzen.net/nachricht/Amgen_SVP_of_North_American_Commercial_Operations_James_Daly_to_Present_at_the_Goldman_Sachs_Healthcare_Conference_738720